Navigation Links
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued
Date:9/11/2009

PARIS and TARRYTOWN, N.Y., Sept. 11 /PRNewswire-FirstCall/ -- Sanofi-aventis (Euronext: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC). As part of a planned interim efficacy analysis, the IDMC determined that the addition of aflibercept to gemcitabine would be unable to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to placebo plus gemcitabine in this study. The types and frequencies of adverse events reported on the combination arm with aflibercept were generally as anticipated.

With the closure of the study, a detailed analysis of the efficacy and safety results will be conducted by the companies and results will be presented at a future medical meeting. Sanofi-aventis and Regeneron have notified the study investigators and appropriate regulatory authorities of the decision to discontinue the study. Patients in the study will continue to be provided access to aflibercept at the determination of the study investigators in consultation with the patients.

Metastatic pancreatic cancer is among the most intractable cancers. Clinical development of new therapies, including anti-VEGF agents, has been generally characterized by a failure to achieve significant incremental clinical benefit over existing treatments.

"We are disappointed with the result of this study and
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.; sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
2. Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
3. MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
4. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
5. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
6. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
7. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
8. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
9. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
10. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA
11. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Chiltern International Limited (Chiltern), a global contract research organization ... of their successful collaboration in Drug Phototoxicity. ... using a validated and regulatory accepted in vivo ... phototoxicity. The history of this collaboration can be traced ...
... 2011 Glenveigh Medical, LLC and Monica Healthcare Limited ... the United States as well as US territories and ... system. The system recently received FDA regulatory clearance for ... name Beacon by Monica™ , the wireless fetal ...
Cached Medicine Technology:Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 2Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 3Glenveigh Medical and Monica Healthcare Announce Distribution Agreement for Groundbreaking FDA Cleared Wireless Fetal Monitoring System 2
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... YORK April 17, 2014 EcoHealth Alliance, a ... health issues, published a comprehensive review today examining the ... Marburg virus. The review calls for improved global surveillance ... as the recent outbreak of Ebola in West Africa ... the countries of Guinea and Liberia. According to ...
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2
... Women experiencing physical abuse from intimate partners spent 42 percent ... to a long-term study of more than 3,000 women. , ... study revealed that women who suffered physical abuse five or ... on health care than women who were never abused. , ...
... Gray of Chicago, IL, will travel to Washington, D.C., ... meet with congressional leaders and gain their support for ... cure for epilepsy.Gray, 9, is one of 37 young ... Speak Up! , a national program coordinated by the ...
... the European UnionEAST PROVIDENCE, R.I., March 23 ... the innovative IlluminOss(TM) Photodynamic Bone Stabilization System for ... granted a CE Mark. The approval permits ... European Union (EU).IlluminOss Medical is beginning the process ...
... Healthcare ProfessionalsVOORHEES, N.J., March 23 The epidemiology ... changing rapidly and has been marked by a ... CDI can be challenging and guidelines for treatment ... effectively implement key strategies for reducing the incidence ...
... African Health Conference in Kenya SILVER SPRING, Md., ... a communications, research, and technology firm, will share the ... mobile video-enabled phones in meeting the requirements for monitoring ... East African Health and Scientific Conference. The findings ...
... MALVERN, Pa., March 23 Fujirebio Diagnostics, Inc., ... leader in cancer biomarker assays, today announced the ... Officer. Dr. Barnes comes to Fujirebio Diagnostics ... has held various positions at Abbott and Meridian ...
Cached Medicine News:Health News:Physical abuse raises women's health costs over 40 percent 2Health News:Illinois Youth Shares Epilepsy Message on Capitol Hill 2Health News:IlluminOss(TM) Photodynamic Bone Stabilization System Receives CE Mark 2Health News:Clostridium difficile Infection in Primary Care: Tackling a Virulent Pathogen 2Health News:Pilot Study Using Video Cell Phones for Mobile Direct Observation Treatment (MDOT) to Monitor Medication Compliance of TB Patients 2Health News:Pilot Study Using Video Cell Phones for Mobile Direct Observation Treatment (MDOT) to Monitor Medication Compliance of TB Patients 3Health News:Pilot Study Using Video Cell Phones for Mobile Direct Observation Treatment (MDOT) to Monitor Medication Compliance of TB Patients 4Health News:Fujirebio Diagnostics Appoints Grady Barnes as Chief Scientific Officer 2
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... NuSieve 3:1 Agarose is a molecular biology grade, ... for fine resolution of small DNA, RNA, and ... enhance the speed of gel processing and blotting. ... resolution of DNA fragments up to 1,000 bp, ...
... standard gelling temperature, high gel strength agarose ... bp. This Genetic Technology Grade™ (GTG) agarose ... DNA recovered from SeaKem GTG Agarose gels ... GTG Agarose is extensively performance tested to ...
... gel strength, high electrophoretic mobility, and ... is the superior choice for CHEF ... easy to handle at concentrations as ... run times. Low background staining also ...
Medicine Products: